| 000 | 01357 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250517060415.0 | ||
| 264 | 0 | _c20160922 | |
| 008 | 201609s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdv485 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMaillet, D | |
| 245 | 0 | 0 |
_aThe reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cJan 2016 |
||
| 300 |
_a192-8 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdverse Drug Reaction Reporting Systems |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 | _aEurope |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 700 | 1 | _aBlay, J Y | |
| 700 | 1 | _aYou, B | |
| 700 | 1 | _aRachdi, A | |
| 700 | 1 | _aGan, H K | |
| 700 | 1 | _aPéron, J | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 27 _gno. 1 _gp. 192-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdv485 _zAvailable from publisher's website |
| 999 |
_c25369554 _d25369554 |
||